Psoriasis — SCE Dermatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — TYK2 (tyrosine kinase 2) inhibitor
Deucravacitinib is a first-in-class selective TYK2 (tyrosine kinase 2) inhibitor — an allosteric inhibitor binding to the regulatory (pseudokinase) domain of TYK2 rather than the catalytic domain. TYK2 mediates signalling of IL-23, IL-12, and type I interferons — key cytokines in psoriasis pathogenesis. Selective TYK2 inhibition preserves JAK1/2/3 function, theoretically reducing the haematological, lipid, and infection risks associated with broader JAK inhibition. Deucravacitinib demonstrated superiority over Apremilast and comparable efficacy to some biologics in clinical trials. It does not require routine blood monitoring. NICE appraisal is ongoing.
Reference: NICE Appraisal; BAD 2020 Psoriasis Guidelines Update